drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (autologous dendritic cell vaccine)
drug_description
Autologous dendritic cell vaccine generated ex vivo from a patient’s peripheral blood monocytes, differentiated into dendritic cells and pulsed with multiple EBV antigens to prime EBV-specific T-cell responses against EBV-positive nasopharyngeal carcinoma; dosed 5×10^6 cells subcutaneously every 2 weeks for 3–5 doses.
nci_thesaurus_concept_id
C200792
nci_thesaurus_definition
A cell-based cancer vaccine composed of autologous monocyte-derived dendritic cells (DCs) pulsed with allogeneic Epstein-Barr virus (EBV)-transformed B-lymphoblastoid cell line (BLCL) lysate, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, DCs are loaded with allogeneic EBV-transformed BLCL lysate. Upon re-administration of the allogeneic EBV-transformed BLCL lysate-pulsed autologous DC vaccine KSD-101, the immune system is exposed to EBV-specific antigens, which stimulates the induction of a specific cytotoxic T-lymphocyte (CTL) response against EBV-positive tumor cells or EBV-infected cells. This results in cell lysis and inhibition of cancer cell proliferation. EBV, a ubiquitous human herpes virus, is associated with various malignancies.
drug_mesh_term
Cancer Vaccines
drug_category
DC VACCINE
drug_class
Vaccine
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Autologous monocyte-derived dendritic cells pulsed ex vivo with EBV antigens are re-administered to present these antigens via MHC I/II, priming and expanding EBV-specific CD8+ cytotoxic T cells and CD4+ helper T cells. The resulting Th1/IFN-γ–biased response targets and lyses EBV-positive tumor cells in nasopharyngeal carcinoma.
drug_name
KSD-101
nct_id_drug_ref
NCT06097793